FRM
GTHX

Fox Run Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Fox Run Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,542
Closed -$128K – 979
2022
Q4 		$128K Buy
+23,542
New +$197K 0.05% 544

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fox Run Management's GTHX Position: Q1 2023 in Review

Fox Run Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2023, closing a stake of 23,542 shares — an estimated $128K sold.

Fox Run Management first reported a position in GTHX in Q4 2022 and held it in 1 quarter. The position peaked at $128K in Q4 2022. 96 funds tracked by Wall St. Rank hold GTHX as of Q1 2023.

  • Fox Run Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Fox Run Management sold 23,542 G1 Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $128K.
  • Fox Run Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Fox Run Management's G1 Therapeutics, Inc. Common Stock position peaked at $128K in Q4 2022.
  • 96 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Fox Run Management's 13F filing for Q1 2023, filed 12 May 2023.